Piramal Enterprises Limited specializes in Non Banking Financial Company (NBFC) within the Financial Services sector.
Piramal Enterprises Limited, with Security Code 500302, is a leading player in the Non Banking Financial Company (NBFC) industry, categorized under the Financial Services sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2022-04-01 | 2022-06-30 | 35,483.70 | 4,859.80 | 37,264.60 | 20.79 | - | 1,780.90 | -1,853.50 | 4,743.70 |
| 2022-04-01 | 2022-06-30 | 5,132.70 | 280.80 | 5,560.40 | 1.18 | - | 427.70 | -56.00 | 323.70 |
| 2022-01-01 | 2022-03-31 | 5,736.40 | 3,162.30 | 8,758.10 | 13.23 | -476.00 | 3,021.70 | -61.60 | 3,606.00 |
| 2022-01-01 | 2022-03-31 | 41,629.40 | 1,505.30 | 44,010.30 | 4.58 | -7,166.00 | 2,380.90 | -1,904.60 | -135.20 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 1% |
| 3 Years: | 28% |
| TTM: | -21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 18% |
| 3 Years: | 85% |
| TTM: | -68% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -3% |
| 3 Years: | -12% |
| 1 Year: | -2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -3% |
| 3 Years: | -8% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -27% |
| 3 Years: | -34% |
| TTM: | -82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -3% |
| 3 Years: | -12% |
| 1 Year: | -2% |
Piramal Pharma, the pharma solutions subsidiary of Piramal Enterprises, has entered into an agreement to acquire a 20% equity stake in Enzyvant Therapeutics, a US-based clinical-stage biotechnology company focused on developing novel genetic therapies for rare diseases.
Piramal Enterprises has partnered with its subsidiary Piramal Capital & Housing Finance (PCHFL) to launch a co-lending platform that will provide loans to affordable housing projects.
Piramal Enterprises reported a 60% year-on-year jump in its consolidated net profit to Rs 944 crore for the quarter ended December 2022 (Q3FY23), driven by strong performance across its businesses.
Piramal Enterprises Limited on Wednesday said that it will sell its pharma business to US-based private equity fund Bain Capital for Rs 3,633 crore as part of its strategy to focus on financial services business.
